VIVEbiotech participa en el proyecto europeo MAGIC
El consorcio MAGIC pretende
tener un impacto significativo en la vida de personas afectadas por distrofias musculares.
top of page
Noticias
Noticias relacionadas con terapia génica y celular.
- Jun 12
CRISPR-Cas:From biology to therapeutic
7–10 November 2023 | Seville, Spain SETGYC fellowships available • Scientific program now available on https://meetings.embo.org/event/...
- Apr 28
Global Awards for Research in DMD-AWARD
Pfizer Global Medical Grants have opened a request for proposals that advance our understanding of Duchenne muscular dystrophy.
- Mar 28
Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network
Read the position paper, published in Bone Marrow Transplantation, from the Spanish Network of Advanced Therapies (TERAV, formerly TerCel).
- Feb 20
WADA invites applications for research projects on the development of gene doping detection methods
The World Anti-Doping Agency (WADA) is pleased to inform you of a call for research projects on the theme of Gene Doping Detection that...
- Jan 11
Nuestras cifras y logros del 2022
Echa un vistazo al resumen de nuestras cifras y logros del 2022.
- Nov 23, 2022
FDA approval of the world’s first gene therapy for Haemophilia
We are incredibly proud to announce the FDA approval of the world’s first #genetherapy for #hemophiliaB. https://lnkd.in/e4SFzMCc
- Jun 8, 2022
SETGYC 2022 Oral and Poster Award Winners
Congratulations to this year's oral and poster award winners, who presented at the SETGYC Biennial Congress in Sevilla.
- May 13, 2022
Outreach opportunity as a translator for EuroGCT
EuroGCT is seeking volunteer scientists who are native speakers of Spanish or other languages to translate gene and cell therapy information
- May 4, 2022
In memory of Dr. Manfred Schmidt
SETGYC would like to express our sadness and dismay at the loss of Dr. Manfred Schmidt.
bottom of page